FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the
Emergency Treatment of Known or Suspected Opioid Overdose

Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines
Expected to Air Sunday, February 24, 2019

Patients Who Receive Information About the Importance of Safe Disposal are Three Times More Likely to Dispose of Unused Prescription Opioid Medications

Eisai and Purdue Pharma Present Efficacy and Safety Data from
Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference:
Advances in Sleep and Circadian Science

Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment

On-Road Driving Safety Study of
Investigational Lemborexant Published in SLEEP^®

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain

First Patient Enrolled in Investigator-Initiated Study of Tinostamustine in Glioblastoma

Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-
Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain